DUBLIN--(BUSINESS WIRE)--The "Transdermal Drug Delivery Systems Market by Type of Delivery System - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to Research and Markets' offering.
The global transdermal drug delivery systems market was valued at $ 32,516 million in 2016, and is projected to reach $61,689 million by 2023, growing at a CAGR of 9.5% from 2017 to 2023. The passive system segment held more than three-fifths share of the total market in 2016.
Transdermal drug delivery systems are used to deliver drug through intact skin at a controlled rate into the systemic circulation. Increase in geriatric population and rise in number of patients suffering from chronic disorders, such as hypertension, diabetes, and angina, are expected to drive the market growth. Moreover, surge in adoption of new delivery system technologies, such as ultrasound, boosts the market growth. However, disadvantages of these delivery systems, such as irritation at the site of application and edema, are expected to impede the market growth.
The passive system segment is expected to dominate the market throughout the analysis period, owing to increase in the incidence of chronic disorders, such as hypertension. The active system segment is expected to register highest CAGR of 12.8% during the forecast period.
- Novartis AG
- Johnson & Johnson
- Mylan N.V.
- Boehringer Ingelheim GmbH
- Bayer AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
- Acrux Limited
- Echo Therapeutics Inc.
Endo Pharmaceuticals Inc.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Executive Summary
Chapter 3 - Market Overview
Chapter 4 - Transdermal Drug Delivery System Market, By Type of Delivery System
Chapter 5 - Transdermal Drug Delivery System Market, By Application
Chapter 6 - Transdermal Drug Delivery System Market, By Region
Chapter 7 - Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/77xxbd/transdermal_drug